Trials / Active Not Recruiting
Active Not RecruitingNCT06924424
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 105 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to evaluate the efficacy and safety of a three drug combination therapy of aponermin, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Aponermin, pomalidomide, dexamethasone | Three drugs combination for R/R MM. Aponermin, 10mg/kg d1-5 Pomalidomide 4mg d1-21 Dexamethasone 20mg d1,d8,d15 Each treatment cycle is 28 days. |
Timeline
- Start date
- 2025-03-01
- Primary completion
- 2026-12-31
- Completion
- 2027-06-30
- First posted
- 2025-04-11
- Last updated
- 2025-04-11
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06924424. Inclusion in this directory is not an endorsement.